Modality
Peptide
MOA
DLL3 ADC
Target
TYK2
Pathway
Tau
WilmsCRCALL
Development Pipeline
Preclinical
Dec 2020
→ Jan 2028
PreclinicalCurrent
NCT06912143
2,067 pts·CRC
2025-10→2026-04·Recruiting
NCT04700552
596 pts·CRC
2020-12→2028-01·Terminated
2,663 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-284w awayInterim· CRC
2028-01-181.8y awayInterim· CRC
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
Preclinical
Termina…
Preclinical
Recruit…
Catalysts
Interim
2026-04-28 · 4w away
CRC
Interim
2028-01-18 · 1.8y away
CRC
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06912143 | Preclinical | CRC | Recruiting | 2067 | HAM-D |
| NCT04700552 | Preclinical | CRC | Terminated | 596 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| COR-9566 | Corcept | Approved | TYK2 | |
| SND-9531 | Syndax | Phase 3 | TYK2 | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| RAR-1117 | Ultragenyx | Phase 1/2 | TYK2 | |
| Datocilimab | Neumora | Phase 1 | TYK2 |